MEMarwa Tarek ElRakaiby

Marwa Tarek ElRakaiby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marwa Tarek ElRakaiby has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The coadministration of Lactobacillus probiotic augments the antitumor effect of telmisartan in rats

    by Ahmed M. El-Baz, Amany A. El-Mahmoudy, Sameh Saber, Marwa T. ElRakaiby

    Colorectal cancer (CRC) is a prevalent disease with a high mortality rate and is significantly affected by microbial dysbiosis. Recent research suggests that modulation of the gut microbiome can have therapeutic benefits and that Angiotensin-II Type 1 Receptor (AT1R) can stimulate cell growth, angiogenesis, and resistance to apoptosis in various cancers. In this study, the adjunctive administration of Lactobacillus spp. and telmisartan, an AT1R blocker, was explored in the treatment of CRC. The effect of telmisartan and a mixture of probiotic species, Lactobacillus delbrueckii and Lactobacillus fermentum, was assessed on key biomarkers and selected gut microbiota taxa in 1,2-dimethylhydrazine-induced CRC in rats. Angiogenesis, inflammation, and apoptosis were assessed by measuring vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA), Interleukin 6 (IL-6), and Annexin V levels, respectively. The relative abundance of selected gut microbial taxa, including Bacteroides spp., Clostridium spp., Clostridium coccoides, Ruminococcus spp., and Lactobacillus spp. was analyzed to determine the change in the microbial composition in the different experimental groups of the animal model. This study demonstrated that the unique combination therapy using a Lactobacillus mixture and telmisartan effectively reduced VEGF and IL-6 levels, indicating decreased angiogenesis and inflammation. Lactobacillus spp. co-administration with telmisartan boosted programmed cell death, reversed dysbiosis, improved histopathological outcomes, and reduced CEA levels. These findings offer a new perspective on the role of Lactobacillus spp. and telmisartan in CRC treatment. Further research on their adjunctive use and therapeutic potential are needed to enhance clinical efficacy.


  • Open Access

    Algal–bacterial bioremediation of cyanide-containing wastewater in a continuous stirred photobioreactor

    by Mona F. AbdelMageed, Marwa T. ElRakaiby

    This study reports the isolation and characterization of highly resistant bacterial and microalgal strains from an Egyptian wastewater treatment station to cyanide-containing compounds. The bacterial strain was identified as Bacillus licheniformis by 16S rRNA gene sequencing. The isolate removed up to 1 g L−1 potassium cyanide, 3 g L−1 benzonitrile, and 1 g L−1 sodium salicylate when incubated as 10% v/v in MSM at 30 ℃. However, it failed to degrade potassium thiocyanate at all tested concentrations. The microalgal isolate was identified by electron microscopy as a strain of Chlorella spp.. Algal toxicity was tested by incubating the microalgae as 6% v/v in MSM containing 2 g L− 1 NaHCO3 with increasing concentrations of the pollutants. Results showed that 0.05 g L−1 KCN, 1.5 g L−1 benzonitrile, 5 g L −1 KSCN, and 5 g L−1 sodium salicylate inhibited 93%, 96%, 75%, and 21% of algal growth, respectively. In a continuous stirred photobioreactor, the bacterial-microalgal microcosm detoxified synthetic wastewater containing 0.2 g L−1 KCN, 0.1 g L−1 benzonitrile, and 0.5 g L−1 sodium salicylate in 3.5 days of hydraulic retention time. System failure was recorded when the KCN concentration was increased to 0.25 g L−1. The effluent had no inhibitory effect on the germination of Lepidium sativum seeds in phytotoxicity testing. Temperature, pH, and chitosan effects were assessed on the algal/bacterial settleability. Statistical analysis showed no significant difference between the tested parameters. The microcosm represents a potential candidate for the treatment of industrial wastewater containing cyanide compounds.


  • Open Access

    Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients

    by Doaa Bsc Mohamed Abdelnajid, Ahmed Y. Elmowafy, Lionel Rostaing, Marwa T. Elrakaiby

    Some hepatitis-C virus patients have resistance to direct-acting-antivirals (DAAs). Genetic polymorphisms have been associated with drug resistance. This study aimed to evaluate the role of interleukin (IL)-28B gene polymorphism and IL-12 levels as predictors for a response to sofosbuvir/ribavirin (SOF/RBV) with (triple-therapy) or without (dual-therapy) Peg-alpha-interferon. 92 hepatitis C virus (HCV)/RNA (+)-patients treated with dual (n = 72) or triple (n = 20) therapy. IL28B genetic polymorphism and IL-12 level assessments. 30.4% of the patients were IL28B C/C genotype, 56.5% C/T-genotype, and 13% T/T-genotype. Mean baseline IL-12 levels were 27.5 ± 3.0 pg/mL. Rapid viral response was achieved in 86/92 patients. All patients achieved end-of-treatment virologic response. The 12- and 24-week sustained virologic responses (SVR) were achieved in 76 patients (82.6%), that is, a relapse was found in 16 patients (17.4%). 8 and 12-weeks after antiviral therapy, IL-12 levels decreased significantly, and became comparable to those of the control-group. That drop in IL-12 levels was similar across the dual- and triple-therapy patients. Finally, logistic regression analysis showed that the increase in baseline aspartate aminotransferase (AST) and T/T genotyping had an independent effect on increasing the probability a SVR failing in both dual- and triple-therapy groups (P = .0007 and P = .02, respectively). Single-nucleotide polymorphism (SNP) in IL-28B and IL-12 levels play roles as predictors in DAAs resistance.


  • Open Access

    Antibacterial and Anti-Inflammatory Activities of Thymus vulgaris Essential Oil Nanoemulsion on Acne Vulgaris

    by Farah M. Abdelhamed, Nourtan F. Abdeltawab, Marwa T. ElRakaiby, Rehab N. Shamma, Nayera A. Moneib

    Antibiotics are frequently used in acne treatment and their prolonged use has led to an emergence of resistance. This study aimed to investigate the use of natural antimicrobials as an alternative therapy. The antimicrobial and anti-inflammatory activities of five commonly used essential oils (EOs) (tea tree, clove, thyme, mentha and basil EOs), and their possible mechanisms of action against Cutibacterium acnes and Staphylococcus epidermidis, were explored. The effect of the most potent EO on membrane permeability was elucidated and its anti-inflammatory action, when formulated as nanoemulsion, was tested in an in vivo acne model. The in vitro studies showed that thyme EO had the most potent antimicrobial and antibiofilm activity, with phenolics and terpenoids as main antimicrobial constituents of EO. Thyme EO affected cell membrane permeability of both bacterial species, evident by the detection of the leakage of intracellular ions and membrane integrity by the leakage of nucleic acids. Morphological alteration in bacterial cells was confirmed by transmission electron microscopy. Thyme EO nanoemulsion led to the suppression of an inflammatory response in acne animal models along with a bacterial load decrease and positive histopathological changes. Collectively, thyme EO nanoemulsion showed potent antimicrobial and anti-inflammatory effects compared to the reference antibiotics, suggesting its effectiveness as a natural alternative in acne treatment.


  • Open Access

    A novel PCR method targeting staphostatin genes differentiates Staphylococcus aureus from Staphylococcus epidermidis in clinical isolates and nasal microbiome samples

    by Marina Zoheir Ghattas, Marwa Tarek ElRakaiby, Ramy Karam Aziz, Hamdallah H. Zedan

    Staphylococcus aureus is a pathogen associated with community-acquired and healthcare-associated infections, and is known for rapid acquisition of resistance to multiple antibiotics. Staphylococcus epidermidis is another staphylococcal species commonly seen as a commensal, but may cause opportunistic infections. These two closely related species may naturally co-colonize and inhabit the human skin and nose; thus it is important to develop methods to differentiate between them. Conventional differentiation methods (e.g., mannitol salt agar, coagulase test, Analytical Profile Index kits) require culturing and isolating the bacteria, while molecular methods based on polymerase chain reaction (PCR) or sequencing are culture independent, highly accurate, and sensitive. They may be objectively interpreted and can be adapted for high-throughput assays. Here, we aimed to develop a rapid and accurate method to differentiate mixtures of S. aureus and S. epidermidis in clinical isolates and microbiome samples. Using comparative genomics tools (e.g., MetaRef and PATRIC bioinformatics resource center), we compared the core and pan genomes of S. aureus and S. epidermidis to determine signature genes for each species. Among candidate genes, we chose the virulence genes, staphostatin B and staphostatin A as genetic biomarkers for S. aureus and S. epidermidis, respectively. We designed PCR primers that target specific sequences within each gene and tested them on DNA isolated from laboratory strains, clinical isolates, nasal isolates, and nasal swabs. Our developed method is simple, specific, sensitive, and can be applied to metagenomic samples as well as competition or co-evolution studies in which the two organisms are co-cultured.

  • Open Access

    A novel PCR method targeting staphostatin genes differentiates Staphylococcus aureus from Staphylococcus epidermidis in clinical isolates and nasal microbiome samples

    by Marina Zoheir Ghattas, Marwa Tarek ElRakaiby, Ramy Karam Aziz, Hamdallah H. Zedan

    Staphylococcus aureus is a pathogen associated with community-acquired and healthcare-associated infections, and is known for rapid acquisition of resistance to multiple antibiotics. Staphylococcus epidermidis is another staphylococcal species commonly seen as a commensal, but may cause opportunistic infections. These two closely related species may naturally co-colonize and inhabit the human skin and nose; thus it is important to develop methods to differentiate between them. Conventional differentiation methods (e.g., mannitol salt agar, coagulase test, Analytical Profile Index kits) require culturing and isolating the bacteria, while molecular methods based on polymerase chain reaction (PCR) or sequencing are culture independent, highly accurate, and sensitive. They may be objectively interpreted and can be adapted for high-throughput assays. Here, we aimed to develop a rapid and accurate method to differentiate mixtures of S. aureus and S. epidermidis in clinical isolates and microbiome samples. Using comparative genomics tools (e.g., MetaRef and PATRIC bioinformatics resource center), we compared the core and pan genomes of S. aureus and S. epidermidis to determine signature genes for each species. Among candidate genes, we chose the virulence genes, staphostatin B and staphostatin A as genetic biomarkers for S. aureus and S. epidermidis, respectively. We designed PCR primers that target specific sequences within each gene and tested them on DNA isolated from laboratory strains, clinical isolates, nasal isolates, and nasal swabs. Our developed method is simple, specific, sensitive, and can be applied to metagenomic samples as well as competition or co-evolution studies in which the two organisms are co-cultured.

  • Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug–microbiome interactions

    by Ramy K. Aziz, Shaimaa M. Hegazy, Reem Yasser, Mariam R. Rizkallah, Marwa T. ElRakaiby

    Introduction: Pharmacomicrobiomics and toxicomicrobiomics study how variations within the human microbiome (the combination of human-associated microbial communities and their genomes) affect drug disposition, action, and toxicity. These emerging fields, interconnecting microbiology, bioinformatics, systems pharmacology, and toxicology, complement pharmacogenomics and toxicogenomics, expanding the scope of precision medicine. Areas covered: This article reviews some of the most recently reported pharmacomicrobiomic and toxicomicrobiomic interactions. Examples include the impact of the human gut microbiota on cardiovascular drugs, natural products, and chemotherapeutic agents, including immune checkpoint inhibitors. Although the gut microbiota has been the most extensively studied, some key drug-microbiome interactions involve vaginal, intratumoral, and environmental bacteria, and are briefly discussed here. Additionally, computational resources, moving the field from cataloging to predicting interactions, are introduced. Expert opinion: The rapid pace of discovery triggered by the Human Microbiome Project is moving pharmacomicrobiomic research from scattered observations to systematic studies focusing on screening microbiome variants against different drug classes. Better representation of all human populations will improve such studies by avoiding sampling bias, and the integration of multiomic studies with designed experiments will allow establishing causation. In the near future, pharmacomicrobiomic testing is expected to be a key step in screening novel drugs and designing precision therapeutics.


  • The Nile River Microbiome Reveals a Remarkably Stable Community Between Wet and Dry Seasons, and Sampling Sites, in a Large Urban Metropolis (Cairo, Egypt)

    by Walaa A. Eraqi, Marwa T. ElRakaiby, Salwa A. Megahed, Noha H. Yousef, Mostafa S. Elshahed, Aymen S. Yassin

    World freshwater supplies are in need of microbiome diversity analyses as a first step to future ecological studies, and to monitor water safety and quality. The Nile is a major north-flowing river in Africa that displays both spatial and temporal variations in its water quality. Here, we present the first microbiome analysis of the Nile River water in two seasons: (1) summer representing the wet season, and (2) winter representing the dry season, as sampled around Cairo, the capital of Egypt. Surface river water samples were collected from selected locations along the path of river, and the microbial composition was analyzed by next-generation sequencing of the 16S rRNA gene. We found a striking stability in the Nile microbiome community structure along the examined geographical urban sites and between the wet and dry seasons as evidenced by the high proportion of shared operational taxonomic unit values among all samples. The community was dominated by the Cyanobacteria (mainly Synechococcus ), Actinobacteria candidate family (ACK-M1), and Proteobacteria (mainly family Comamonadaceae ). Among these dominant taxa, Synechococcus exhibited seasonal driven variation in relative abundance. Other taxa were predominantly rare across all seasons and locations, including genera members of which have been implicated as pathogens such as Acinetobacter , Aeromonas , and Legionella . In addition, comparisons with data on freshwater microbiome in other world regions suggest that surface water communities in large rivers exhibit limited variation. Our results offer the first insights on microbial composition in one of the most notable rivers near a large metropolis.


  • Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS/MS: A key step towards personalized therapeutics

    by Medhat A. Al-Ghobashy, Samah M. Kamal, Ghada M. El-Sayed, Ali K. Attia, Mohamed Nagy, Ahmed ElZeiny, Marwa T. Elrakaiby, Mohammed M. Nooh, Maggie Abbassi, Ramy K. Aziz


  • Pharmacomicrobiomics: The Impact of Human Microbiome Variations on Systems Pharmacology and Personalized Therapeutics

    by Marwa ElRakaiby, Bas E. Dutilh, Mariam R. Rizkallah, Annemarie Boleij, Jason N. Cole, Ramy K. Aziz

    The Human Microbiome Project (HMP) is a global initiative undertaken to identify and characterize the collection of human-associated microorganisms at multiple anatomic sites (skin, mouth, nose, colon, vagina), and to determine how intra-individual and inter-individual alterations in the microbiome influence human health, immunity, and different disease states. In this review article, we summarize the key findings and applications of the HMP that may impact pharmacology and personalized therapeutics. We propose a microbiome cloud model , reflecting the temporal and spatial uncertainty of defining an individual's microbiome composition, with examples of how intra-individual variations (such as age and mode of delivery) shape the microbiome structure. Additionally, we discuss how this microbiome cloud concept explains the difficulty to define a core human microbiome and to classify individuals according to their biome types. Detailed examples are presented on microbiome changes related to colorectal cancer, antibiotic administration, and pharmacomicrobiomics, or drug–microbiome interactions, highlighting how an improved understanding of the human microbiome, and alterations thereof, may lead to the development of novel therapeutic agents, the modification of antibiotic policies and implementation, and improved health outcomes. Finally, the prospects of a collaborative computational microbiome research initiative in Africa are discussed.